All Press Releases

August 30, 2023

Recludix Pharma to Participate in Multiple Investor Conferences in September

Read More »
July 20, 2023

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

Read More »
March 7, 2023

Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

Read More »
February 1, 2023

Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference

Read More »
January 6, 2023

Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More »
October 20, 2022

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology

Read More »
September 29, 2022

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

Read More »
September 13, 2022

Recludix Pharma Announces the Appointment of Seasoned Biotech Leader Athena Countouriotis, M.D., as the Chairperson of the Board of Directors

Read More »
January 6, 2022

Recludix Pharma Announces Scientific Advisory Board

Read More »
November 15, 2021

Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO

Read More »
MENU